Suscribirse

Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma - 18/09/19

Doi : 10.1016/j.biopha.2019.109211 
Yang Zhang a, Neil Gross b, Zufei Li a, c, Gaofei Yin a, Qi Zhong a, Chuan Liu d, Zhigang Huang a,
a Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Key Laboratory of Otolaryngology Head and Neck Surgery (Capital Medical University), Ministry of Education, Beijing, 100730, China 
b Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
c Department of Otolaryngology Head and Neck Surgery, Aerospace Center Hospital, Beijing, 100039, China 
d Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China 

Corresponding author at: Beijing Tongren Hospital, Capital Medical University, Key Laboratory of Otolaryngology Head and Neck Surgery, (Capital Medical University), Ministry of Education, No1Dongjiaominxiang, Dongcheng District, Beijing, 100730, China.Beijing Tongren HospitalCapital Medical UniversityKey Laboratory of Otolaryngology Head and Neck Surgery(Capital Medical University)Ministry of EducationNo1DongjiaominxiangDongcheng DistrictBeijing100730China

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 10
Iconografías 8
Vídeos 0
Otros 0

Graphical abstract




The expression of BTF3 is overexpressed in HSCC and is associated with lymph node metastasis and survival. Our in vitro and in vivo experiments have shown that BTF3 knockdown significantly impaired regulation of proliferation, cell cycle, and apoptosis, potentially via ATM signaling pathway and demonstrated that BTF3 functioned as an oncogene in the development and progression of HSCC tumors.

El texto completo de este artículo está disponible en PDF.

Highlights

BTF3 is upregulated in HSCC compared with adjacent normal tissues.
BTF3 expression is significantly associated with advanced disease stage and survival.
In vitro experiments indicate BTF3 affects proliferation, cell cycle and apoptosis via ATM pathway.
In vivo experiments support an oncogenic role of BTF3 in progression and development of HSCC.

El texto completo de este artículo está disponible en PDF.

Abstract

Purpose

The BTF3 is involved in oncogenesis, while the biological roles in HSCC remain unclear. The aim of this study was to explore the impact of BTF3 knockdown on biological phenotypes of human HSCC in vivo and in vitro.

Methods

The expression of BTF3 was assessed in HSCC and normal tissues. In vitro experiments were performed to explore impact of BTF3 knockdown on biological phenotypes of human HSCC cell line, including proliferation, cell cycle, and apoptosis. Moreover, nude mice were used to evaluate growth of xenograft tumors. Finally, gene chip was used to explore the potential signaling pathways of BTF3, with confirmation of potential BTF3-related genes.

Results

Our results showed elevated expression of BTF3 was observed in HSCC tumors compared to paired adjacent normal tissues in 68 patients, and positively associated with lymph node metastasis and survival of this HSCC patient cohort. In addition, in vitro experiments showed that BTF3 knockdown significantly impaired regulation of proliferation, cell cycle, and apoptosis, potentially via ATM signaling pathway. Finally, in vivo experiments demonstrated that BTF3 functioned as an oncogene by promoting the development and progression of HSCC tumors, indicating its oncogenic role in HSCC.

Conclusions

This study for the first time demonstrated that expression of BTF3 is upregulated in HSCC tumors and this upregulation is positively correlated with lymph node metastasis of this malignancy. The oncogenic role of BTF3 is further validated for tumor promotion and progression of HSCC in vivo, indicating that BTF3 is a potential therapeutic target and prognostic biomarker for HSCC.

El texto completo de este artículo está disponible en PDF.

Abbreviations : BTF3, HSCC, CRISPR/Cas9

Keywords : BTF3, HSCC, CRISPR/Cas9, Knockout


Esquema


© 2019  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118

Artículo 109211- octobre 2019 Regresar al número
Artículo precedente Artículo precedente
  • 4-XL-PPD, a novel ginsenoside derivative, as potential therapeutic agents for gastric cancer shows anti-cancer activity via inducing cell apoptosis medicated generation of reactive oxygen species and inhibiting migratory and invasive
  • Xu De Wang, Yuan Yuan Sun, Fan Zhi Qu, Guang Yue Su, Yu Qing Zhao
| Artículo siguiente Artículo siguiente
  • FALEC exerts oncogenic properties to regulate cell proliferation and cell-cycle in endometrial cancer
  • Qing-Hong Zheng, Lei Shi, Hua-Li Li

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.